Tango Therapeutics, Inc. — Director's Dealing 2025

Feb 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2025-02-03

Reporting Person: Crystal Adam (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-03	Common Stock	A	53015	—	Acquired	172493	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-03	Stock Option (Right to Buy)	$2.91	A	318090	Acquired	2035-02-03	Common Stock (318090)	Direct

Footnotes

F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

F2: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.